Approaches to Ras signaling modulation and treatment of Ras-dependent disorders: A patent review (2007 present)

Expert Opinion on Therapeutic Patents

Volumn 22, Issue 11, 2012, Pages 1263-1287

  Sacco, Elena ^a,b   Spinelli, Michela ^a,b   Vanoni, Marco ^a,b  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b SysBio Center Milano   (Italy)

Author keywords

Cancer; Cell cycle; Ras; Systems biology

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 2 [4 (2 DIMETHYLAMINOETHOXY)PHENYL] 4 (1 HYDROXYIMINO 5 INDANYL) 5 (4 PYRIDINYL) 1H IMIDAZOLE; 3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; CHIR 265; ERASTIN; L 778123; LANPERISONE; LONAFARNIB; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; N [3 (5 CHLORO 1H PYRROLO[2,3 B]PYRIDINE 3 CARBONYL) 2,4 DIFLUOROPHENYL]PROPANESULFONAMIDE; ONCOLYTIC VIRUS; ONCRASIN 1; PF 03758309; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE INHIBITOR; RAF PROTEIN; RAS PROTEIN; REOLYSIN; SALIRASIB; SELUMETINIB; SORAFENIB; TIPIFARNIB; TRAMETINIB; UNCLASSIFIED DRUG; VEMURAFENIB; XL 281; XL 518;

CANCER CELL; CELL KILLING; CELL PROLIFERATION; CELLULAR DISTRIBUTION; DOWN REGULATION; DRUG DOSE ESCALATION; ENZYME INHIBITION; GENE EXPRESSION; HUMAN; ISOPRENYLATION; LETHALITY; MOLECULARLY TARGETED THERAPY; NEOPLASM; NONHUMAN; ONCOGENE RAS; ONCOLYTIC VIROTHERAPY; PALMITOYLATION; PATENT; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; REVIEW; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SOLID TUMOR; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DESIGN; ENZYME INHIBITORS; GENES, RAS; HUMANS; MOLECULAR STRUCTURE; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASMS; PATENTS AS TOPIC; PROTEIN CONFORMATION; RAS PROTEINS; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84867823102     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2012.728586     Document Type: Review

References (135)

1. Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. RAS oncogenes: Weaving a tumorigenic web. Nat Rev Cancer 2011;11(11):761-74
2. Hingorani SR, Tuveson DA. Ras redux: Rethinking how and where Ras acts. Curr Opin Genet Devel 2003;13(1):6-13
3. Mitin N, Rossman KL, Der CJ. Signaling interplay in Ras superfamily function. Curr Biol 2005;15(14):R563-74
4. Vetter IR, Wittinghofer A. The guanine nucleotide-binding switch in three dimensions. Science 2001;294(5545):1299-304
5. Wittinghofer A. Signal transduction via Ras. Biol Chem 1998;379(8-9):933-7
6. Bos JL, Rehmann H, Wittinghofer A. GEFs and GAPs: Critical elements in the control of small G proteins. Cell 2007;129(5):865-77
7. Vigil D, Cherfils J, Rossman KL, et al. Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy? Nat Rev Cancer 2010;10(12):842-57
8. Omerovic J, Laude AJ, Prior IA. Ras proteins: Paradigms for compartmentalised and isoform-specific signalling. Cell Mol Life Sci 2007;64(19-20):2575-89
9. Prior IA, Hancock JF. Ras trafficking, localization and compartmentalized signalling. Semin Cell Dev Biol 2012;23(2):145-53
10. Hancock JF, Paterson H, Marshall CJ. A polybasic domain or palmitoylation is required in addition to the CAAX motif to localize p21ras to the plasma membrane. Cell 1990;63(1):133-9
11. Laude AJ, Prior IA. Palmitoylation and localisation of RAS isoforms are modulated by the hypervariable linker domain. J Cell Sci 2008;121(Pt 4):421-7
12. Ahearn IM, Haigis K, Bar-Sagi D, et al. Regulating the regulator: Post-translational modification of RAS. Nat Rev Mol Cell Biol 2011;13(1):39-51
13. Xu L, Lubkov V, Taylor LJ, et al. Feedback regulation of Ras signaling by Rabex-5-mediated ubiquitination. Curr Biol 2010;20(15):1372-7
14. Kim SE, Yoon JY, Jeong WJ, et al. H-Ras is degraded by Wnt/beta-catenin signaling via beta-TrCP-mediated polyubiquitylation. J Cell Sci 2009;122(Pt 6):842-8
15. Sasaki AT, Carracedo A, Locasale JW, et al. Ubiquitination of K-Ras enhances activation and facilitates binding to select downstream effectors. Sci Signal 2011;4(163):ra13
16. Yang MH, Nickerson S, Kim ET, et al. Regulation of RAS oncogenicity by acetylation. Proc Natl Acad Sci USA 2012. 109(27):10843-8
17. Baker TL, Zheng H, Walker J, et al. Distinct rates of palmitate turnover on membrane-bound cellular and oncogenic H-ras. J Biol Chem 2003;278(21):19292- 300
18. Goodwin JS, Drake KR, Rogers C, et al. Depalmitoylated Ras traffics to and from the Golgi complex via a nonvesicular pathway. J Cell Biol 2005;170(2):261-72
19. Rocks O, Peyker A, Kahms M, et al. An acylation cycle regulates localization and activity of palmitoylated Ras isoforms. Science 2005;307(5716):1746-52
20. Smotrys JE, Linder ME. Palmitoylation of intracellular signaling proteins: Regulation and function. Annu Rev Biochem 2004;73:559-87
21. Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell 1990;61(2):203-12
22. Pelicci G, Lanfrancone L, Grignani F, et al. A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction. Cell 1992;70(1):93-104
23. Li N, Batzer A, Daly R, et al. Guanine-nucleotide-releasing factor hSos1 binds to Grb2 and links receptor tyrosine kinases to Ras signalling. Nature 1993;363(6424):85-8
24. Rozakis-Adcock M, Fernley R, Wade J, et al. The SH2 and SH3 domains of mammalian Grb2 couple the EGF receptor to the Ras activator mSos1. Nature 1993;363(6424):83-5
25. Corbalan-Garcia S, Margarit SM, Galron D, et al. Regulation of Sos activity by intramolecular interactions. Mol Cell Biol 1998;18(2):880-6
26. Quilliam LA. New insights into the mechanisms of SOS activation. Sci STKE 2007(414):pe467
27. Sacco E, Farina M, Greco C, et al. Regulation of hSos1 activity is a system-level property generated by its multi-domain structure. Biotechnol Adv 2012;30(1):154-68
28. Quilliam LA, Rebhun JF, Castro AF. A growing family of guanine nucleotide exchange factors is responsible for activation of Ras-family GTPases. Prog Nucleic Acid Res Mol Biol 2002;71:391-444
29. Bernards A. GAPs galore! A survey of putative Ras superfamily GTPase activating proteins in man and Drosophila. Biochim Biophys Acta 2003;1603(2):47-82
30. Pamonsinlapatham P, Hadj-Slimane R, Lepelletier Y, et al. P120-Ras GTPase activating protein (RasGAP): A multi-interacting protein in downstream signaling. Biochimie 2009;91(3):320-8
31. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev 2003;3(1):11-22
32. Yoon S, Seger R. The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors 2006;24(1):21-44
33. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002;296(5573):1655-7
34. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006;7(8):606-19
35. Duronio V. The life of a cell: Apoptosis regulation by the PI3K/PKB pathway. Biochem J 2008;415(3):333-44
36. Lambert JM, Lambert QT, Reuther GW, et al. Tiam1 mediates Ras activation of Rac by a PI(3)K-independent mechanism. Nat Cell Biol 2002;4(8):621-5
37. Arias-Romero LE, Chernoff J. A tale of two Paks. Biol Cell 2008;100(2):97-108
38. Perona R, Montaner S, Saniger L, et al. Activation of the nuclear factor-kappaB by Rho, CDC42, and Rac-1 proteins. Genes Dev 1997;11(4):463-75
39. Eswaran J, Soundararajan M, Knapp S. Targeting group II PAKs in cancer and metastasis. Cancer Metastasis Rev 2009;28(1-2):209-17
40. Ferro E, Trabalzini L. RalGDS family members couple Ras to Ral signalling and that's not all. Cell Signal 2010;22(12):1804-10
41. Feig L. Ral-GTPases: Approaching their 15 minutes of fame. Trends Cell Biol 2003;13(8):419-25
42. Lim KH, Baines AT, Fiordalisi JJ, et al. Activation of RalA is critical for Ras-induced tumorigenesis of human cells. Cancer Cell 2005;7(6):533-45
43. Bunney TD, Katan M. Phospholipase C epsilon: Linking second messengers and small GTPases. Trends Cell Biol 2006;16(12):640-8
44. Prior IA, Lewis PD, Mattos C. A comprehensive survey of Ras mutations in cancer. Cancer Res 2012;72(10):2457-67
45. Gaglio D, Metallo CM, Gameiro PA, et al. Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth. Mol Syst Biol 2011;7:523
46. Chiaradonna F, Sacco E, Manzoni R, et al. Ras-dependent carbon metabolism and transformation in mouse fibroblasts. Oncogene 2006;25(39):5391-404
47. Anastasiou D, Cantley LC. Breathless cancer cells get fat on glutamine. Cell Res 2012;22(3):443-6
48. Locasale JW, Grassian AR, Melman T, et al. Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat Genet 2011;43(9):869-74
49. Metallo CM, Gameiro PA, Bell EL, et al. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature 2011;481(7381):380-4
50. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011;144(5):646-74
51. Alberghina L, Gaglio D, Gelfi C, et al. Cancer cell growth and survival as a system-level property sustained by enhanced glycolysis and mitochondrial metabolic remodeling. Front Physiol 2012; In press
52. Scheffzek K, Ahmadian MR, Kabsch W, et al. The Ras-RasGAP complex: Structural basis for GTPase activation and its loss in oncogenic Ras mutants. Science 1997;277(5324):333-8
53. Palmioli A, Sacco E, Airoldi C, et al. Selective cytotoxicity of a bicyclic Ras inhibitor in cancer cells expressing K-Ras (G13D). Biochem Biophys Res Commun 2009;386(4):593-7
54. Vizan P, Boros LG, Figueras A, et al. K-ras codon-specific mutations produce distinctive metabolic phenotypes in NIH3T3 mice [corrected] fibroblasts. Cancer Res 2005;65(13):5512-15
55. Forbes SA, Bhamra G, Bamford S, et al. The Catalogue of Somatic Mutations in Cancer (COSMIC). Curr Protoc Hum Genet 2008;Chapter 10:Unit 10 11
56. DeNicola G, Tuveson D. RAS in cellular transformation and senescence. Eur J Cancer 2009;45(Suppl 1):211-16
57. Karnoub A, Weinberg R. Ras oncogenes: Split personalities. Nat Rev Mol Cell Biol 2008;9(7):517-31
58. Chin L, Tam A, Pomerantz J, et al. Essential role for oncogenic Ras in tumour maintenance. Nature 1999;400(6743):468-72
59. Cengel KA, Voong KR, Chandrasekaran S, et al. Oncogenic K-Ras signals through epidermal growth factor receptor and wild-type H-Ras to promote radiation survival in pancreatic and colorectal carcinoma cells. Neoplasia 2007;9(4):341-8
60. Samuels Y, Waldman T. Oncogenic mutations of PIK3CA in human cancers. Curr Top Microbiol Immunol 2010;347:21-41
61. Aoki Y, Niihori T, Narumi Y, et al. The RAS/MAPK syndromes: Novel roles of the RAS pathway in human genetic disorders. Hum Mutat 2008;29(8):992-1006
62. Niihori T, Aoki Y, Narumi Y, et al. Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome. Nat Genet 2006;38(3):294-6
63. Schubbert S, Zenker M, Rowe SL, et al. Germline KRAS mutations cause Noonan syndrome. Nat Genet 2006;38(3):331-6
64. Dasgupta B, Gutmann DH. Neurofibromatosis 1: Closing the GAP between mice and men. Curr Opin Genet Dev 2003;13(1):20-7
65. Tsimberidou AM, Chandhasin C, Kurzrock R. Farnesyltransferase inhibitors: Where are we now? Expert Opin Investig Drugs 2010;19(12):1569-80
66. Holstein SA, Hohl RJ. Is there a future for prenyltransferase inhibitors in cancer therapy? Curr Opin Pharmacol 2012; doi.org/10.1016/j. coph.2012.06.013
67. Berndt N, Hamilton AD, Sebti SM. Targeting protein prenylation for cancer therapy. Nat Rev 2011;11(11):775-91
68. Tsimberidou AM, Rudek MA, Hong D, et al. Phase 1 first-in-human clinical study of S-trans,trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors. Cancer Chemother Pharmacol 2010;65(2):235-41
69. Dekker FJ, Hedberg C. Small molecule inhibition of protein depalmitoylation as a new approach towards downregulation of oncogenic Ras signalling. Bioorg Med Chem 2010;19(4):1376-80
70. Bivona TG, Quatela SE, Bodemann BO, et al. PKC regulates a farnesyl-electrostatic switch on K-Ras that promotes its association with Bcl-XL on mitochondria and induces apoptosis. Mol Cell 2006;21(4):481-93
71. McCubrey JA, Steelman LS, Chappell WH, et al. Roles of the Raf/ MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 2007;1773(8):1263-84
72. Kato-Stankiewicz J, Hakimi I, Zhi G, et al. Inhibitors of Ras/Raf-1 interaction identified by two-hybrid screening revert Ras-dependent transformation phenotypes in human cancer cells. Proc Natl Acad Sci USA 2002;99(22):14398-403
73. Rosnizeck IC, Graf T, Spoerner M, et al. Stabilizing a weak binding state for effectors in the human ras protein by cyclen complexes. Angew Chem Int Ed Engl 2010;49(22):3830-3
74. Gus-Brautbar Y, Johnson D, Zhang L, et al. The anti-inflammatory TIPE2 is an inhibitor of the oncogenic Ras. Mol Cell 2012;45(5):610-18
75. Baines AT, Xu D, Der CJ. Inhibition of Ras for cancer treatment: The search continues. Future Med Chem 2011;3(14):1787-808
76. Santarpia L, Lippman SM, El-Naggar AK. Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin Ther Targets 16(1):103-19
77. Wong KK. Recent developments in anti-cancer agents targeting the Ras/Raf/ MEK/ERK pathway. Recent Patents Anticancer Drug Discov 2009;4(1):28-35
78. Trujillo JI. MEK inhibitors: A patent review 2008 - 2010. Expert Opin Ther Patents 2011;21(7):1045-69
79. Boston SR, Deshmukh R, Strome S, et al. Characterization of ERK docking domain inhibitors that induce apoptosis by targeting Rsk-1 and caspase-9. BMC Cancer 2011;11:7
80. Crawford JJ, Hoeflich KP, Rudolph J. p21-Activated kinase inhibitors: A patent review. Expert Opin Ther Patents 2012;22(3):293-310
81. Yi C, Maksimoska J, Marmorstein R, et al. Development of small-molecule inhibitors of the group I p21-activated kinases, emerging therapeutic targets in cancer. Biochem Pharmacol 2010;80(5):683-9
82. Ong CC, Jubb AM, Haverty PM, et al. Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells. Proc Natl Acad Sci USA 2011;108(17):7177-82
83. Murray BW, Guo C, Piraino J, et al. Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth. Proc Natl Acad Sci USA 2010;107(20):9446-51
84. Deacon SW, Beeser A, Fukui JA, et al. An isoform-selective, small-molecule inhibitor targets the autoregulatory mechanism of p21-activated kinase. Chem Biol 2008;15(4):322-31
85. Neel NF, Martin TD, Stratford JK, et al. The RalGEF-Ral effector signaling network: The road less traveled for anti-ras drug discovery. Genes Cancer 2011;2(3):275-87
86. Chiocca EA. Oncolytic viruses. Nat Rev Cancer 2002;2(12):938-50
87. Zeyaullah M, Patro M, Ahmad I, et al. Oncolytic viruses in the treatment of cancer: A review of current strategies. Pathol Oncol Res 2012; doi:10.1007/s12253-012-9548-2
88. Strong JE, Coffey MC, Tang D, et al. The molecular basis of viral oncolysis: Usurpation of the Ras signaling pathway by reovirus. EMBO J 1998;17(12):3351-62
89. Norman KL, Hirasawa K, Yang AD, et al. Reovirus oncolysis: The Ras/RalGEF/ p38 pathway dictates host cell permissiveness to reovirus infection. Proc Natl Acad Sci USA 2004; 101(30):11099-104
90. Norman KL, Lee PW. Reovirus as a novel oncolytic agent. J Clin Invest 2000;105(8):1035-8
91. Sinkovics J, Horvath J. New developments in the virus therapy of cancer: A historical review. Intervirology 1993;36(4):193-214
92. Ferrari E, Lucca C, Foiani M. A lethal combination for cancer cells: Synthetic lethality screenings for drug discovery. Eur J Cancer 2010;46(16):2889-95
93. Torrance CJ, Agrawal V, Vogelstein B, et al. Use of isogenic human cancer cells for high-throughput screening and drug discovery. Nat Biotechnol 2001;19(10):940-5
94. Dolma S, Lessnick SL, Hahn WC, et al. Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell 2003;3(3):285-96
95. Guo W, Wu S, Liu J, et al. Identification of a small molecule with synthetic lethality for K-ras and protein kinase C iota. Cancer Res 2008;68(18):7403-8
96. Shaw AT, Winslow MM, Magendantz M, et al. Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stress. Proc Natl Acad Sci USA 2011;108(21):8773-8
97. Guo W, Wu S, Wang L, et al. Interruption of RNA processing machinery by a small compound, 1-[(4-chlorophenyl)methyl]-1H-indole- 3-carboxaldehyde (oncrasin-1). Mol Cancer Ther 2009;8(2):441-8
98. Yagoda N, von Rechenberg M, Zaganjor E, et al. RAS-RAF-MEKdependent oxidative cell death involving voltage-dependent anion channels. Nature 2007;447(7146):864-8
99. Sakitama K, Ozawa Y, Aoto N, et al. Effects of a new centrally acting muscle relaxant, NK433 (lanperisone hydrochloride) on spinal reflexes. Eur J Pharmacol 1997;337(2-3):175-87
100. Scholl C, Frohling S, Dunn IF, et al. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 2009;137(5):821-34
101. Luo J, Emanuele MJ, Li D, et al. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 2009;137(5):835-48
102. Adamson P, Marshall CJ, Hall A, et al. Post-translational modifications of p21rho proteins. J Biol Chem 1992;267(28):20033-8
103. Kato K, Cox AD, Hisaka MM, et al. Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity. Proc Natl Acad Sci USA 1992; 89(14):6403-7
104. O'Dwyer PJ, Gallagher M, Nguyen B, et al. Phase I accelerated dose-escalating safety and pharmacokinetic (PK) study of GGTI-2418, a novel geranylgeranyltransferase I inhibitor in patients with refractory solid tumors. Ann Oncol 2010;21(Supplement2):ii42-4
105. Gonzalez JM, Pla D, Perez-Sala D, et al. A-type lamins and Hutchinson-Gilford progeria syndrome: Pathogenesis and therapy. Front Biosci (Schol Ed) 2011;3:1133-46
106. Flaherty KT, Yasothan U, Kirkpatrick P. Vemurafenib. Nat Rev Drug Discov 2011;10(11):811-12
107. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417(6892):949-54
108. Nazarian R, Shi H, Wang Q, et al. Melanomas acquire resistance to B-RAF (V600E) inhibition by RTK or N-RAS upregulation. Nature 2010;468(7326):973-7
109. Straussman R, Morikawa T, Shee K, et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012;487(7408):500-4
110. Wilson TR, Fridlyand J, Yan Y, et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 2012;487(7408):505-9
111. Palmioli A, Sacco E, Abraham S, et al. First experimental identification of Ras-inhibitor binding interface using a water-soluble Ras ligand. Bioorg Med Chem Lett 2009;19(15):4217-22
112. Sacco E, Abraham SJ, Palmioli A, et al. Binding properties and biological characterization of new sugar-derived Ras ligands. Med Chem Comm 2011;2:396-401
113. Peri F, Airoldi C, Colombo S, et al. Design, synthesis and biological evaluation of sugar-derived Ras inhibitors. ChemBioChem 2005;6(10):1839-48
114. Taveras AG, Remiszewski SW, Doll RJ, et al. Ras oncoprotein inhibitors: The discovery of potent, ras nucleotide exchange inhibitors and the structural determination of a drug-protein complex. Bioorg Med Chem 1997;5(1):125-33
115. Maurer T, Garrenton LS, Oh A, et al. Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity. Proc Natl Acad Sci USA 2012;109(14):5299-304
116. Sun Q, Burke JP, Phan J, et al. Discovery of small molecules that bind to K-Ras and inhibit Sos-mediated activation. Angewandte Chemie (International ed) 2012;51(25):6140-3
117. Vanoni M, Bertini R, Sacco E, et al. Characterization and properties of dominant-negative mutants of the ras-specific guanine nucleotide exchange factor CDC25(Mm). J Biol Chem 1999;274(51):36656-62
118. Sacco E, Fantinato S, Manzoni R, et al. The isolated catalytic hairpin of the Ras-specific guanine nucleotide exchange factor Cdc25Mm retains nucleotide dissociation activity but has impaired nucleotide exchange activity. FEBS Lett 2005;579(30):6851-8
119. Bossu P, Vanoni M, Wanke V, et al. A dominant negative RAS-specific guanine nucleotide exchange factor reverses neoplastic phenotype in K-ras transformed mouse fibroblasts. Oncogene 2000;19(17):2147-54
120. Sacco E, Metalli D, Spinelli M, et al. Novel RasGRF1-derived Tat-fused peptides inhibiting Ras-dependent proliferation and migration in mouse and human cancer cells. Biotechnol Adv 2012;30(1):233-43
121. Patgiri A, Yadav KK, Arora PS, et al. An orthosteric inhibitor of the Ras-Sos interaction. Nat Chem Biol 2011;7(9):585-7
122. Ahmadian MR, Zor T, Vogt D, et al. Guanosine triphosphatase stimulation of oncogenic Ras mutants. Proc Natl Acad Sci USA 1999;96(12):7065-70
123. Kosloff M, Selinger Z. Substrate assisted catalysis - application to G proteins. Trends Biochem Sci 2001;26(3):161-6
124. Yang JY, Widmann C. Antiapoptotic signaling generated by caspase-induced cleavage of RasGAP. Mol Cell Biol 2001;21(16):5346-58
125. Kim HR, Roe JS, Lee JE, et al. A p53-inducible microRNA-34a downregulates Ras signaling by targeting IMPDH. Biochem Biophys Res Commun 2012;418(4):682-8
126. Babij C, Zhang Y, Kurzeja RJ, et al. STK33 kinase activity is nonessential in KRAS-dependent cancer cells. Cancer Res 2011;71(17):5818-26
127. Luo T, Masson K, Jaffe JD, et al. STK33 kinase inhibitor BRD-8899 has no effect on KRAS-dependent cancer cell viability. Proc Natl Acad Sci USA 2012;109(8):2860-5
128. Azoitei N, Hoffmann CM, Ellegast JM, et al. Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33. J Exp Med 2012;209(4):697-711
129. Alberghina L, Chiaradonna F, Vanoni M. Systems biology and the molecular circuits of cancer. ChemBioChem 2004;5(10):1322-33
130. Kitano H. A robustness-based approach to systems-oriented drug design. Nat Rev Drug Discov 2007;6(3):202-10
131. Hase T, Tanaka H, Suzuki Y, et al. Structure of protein interaction networks and their implications on drug design. PLoS Comput Biol 2009;5(10):e1000550
132. Moreno-Sanchez R, Saavedra E, Rodriguez-Enriquez S, et al. Metabolic control analysis indicates a change of strategy in the treatment of cancer. Mitochondrion 2010;10(6):626-39
133. Kitano H. Biological robustness. Nat Rev Genet 2004;5(11):826-37
134. Ward PS, Thompson CB. Metabolic reprogramming: A cancer hallmark even Warburg did not anticipate. Cancer Cell 2012;21(3):297-308
135. Anastasiou D, Cantley LC. Breathless cancer cells get fat on glutamine. Cell Res 2012;22(3):443-6